Results 141 to 150 of about 63,783 (265)

The Utility of SMAD4 and S100P as Diagnostic Immunohistochemical Markers for Pancreatic Ductal Adenocarcinomas in Egyptian Patients. [PDF]

J Microsc Ultrastruct
Amal AM, Ahmed MSM, Hareedy AAM, Khattab HMH, Mahmoud EK.   +4 more
europepmc   +1 more source

Driving Drugs Deeper: Force‐Driven Microneedle Systems for Active Therapy and Their Road Towards Clinical Implementation

Small, EarlyView.
Force‐driven microneedles are presented as active therapeutic microdevices that overcome the diffusion limits of conventional patches. By integrating gas generation, magnetic actuation, cavitation, or iontophoresis, these systems drive payloads deeper into tissue, enabling faster, more controlled delivery and highlighting key design principles and ...
Majed Amini, Phoebe Li, Hamed Shahsavan, Mahla Poudineh   +3 more
wiley   +1 more source

Impact of superior mesenteric artery (SMA) adherent tissue in the context of pancreatic head resections- an observational study. [PDF]

BMC Cancer
Azizian A, Bernhardt M, Rühlmann F, Schild-Suhren S, Crede M, Bösch F, Gärtner D, Ghadimi M, Gaedcke J.   +8 more
europepmc   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Alpha-Fetoprotein Is a Potential Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC): A Case Report. [PDF]

Cancer Rep (Hoboken)
Zhong K, Wu X, Lin X, Xie M, Deng M, Tao Q, Qin W, Peng S.   +7 more
europepmc   +1 more source

PFOA Exposure Elicits Quantitative Lipidomic Changes in the Pancreas in a Mouse Model of Pancreatic Cancer

Environmental Toxicology, EarlyView.
ABSTRACT Pancreatic cancer is the fourth leading cause of cancer deaths in the US and predicted to rise to second by 2030. Several risk factors have been identified as potential contributors to pancreatic cancer development including lifestyle factors and long‐term exposure to occupational and environmental carcinogens.
Barbara A. Hocevar, Lisa M. Kamendulis
wiley   +1 more source

Pancreatoduodenectomy for Pancreatic Cancer after Prior Modified Puestow Procedure: A Case Report. [PDF]

Surg Case Rep
Nagasawa Y, Hirashita T, Miyoshino W, Nakamura S, Kawamura M, Takayama H, Kawano Y, Masuda T, Endo Y, Inomata M.   +9 more
europepmc   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

TNS1 and TNS4 play a potential role in development of pancreatic ductal adenocarcinoma but not TNS2 and TNS3. [PDF]

Cell Adh Migr
Świsłocka N, Pryczynicz A, Dorf J, Zaręba K, Guzińska-Ustymowicz K.   +4 more
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source